NASDAQ:CTXR Citius Pharmaceuticals Q3 2026 Earnings Report $0.60 +0.01 (+2.06%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.60 -0.01 (-0.83%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Citius Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.36Beat/MissBeat by +$0.02One Year Ago EPSN/ACitius Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$5.46 millionBeat/MissN/AYoY Revenue GrowthN/ACitius Pharmaceuticals Announcement DetailsQuarterQ3 2026Date8/14/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Citius Pharmaceuticals Earnings HeadlinesCitius Pharmaceuticals Highlights LYMPHIR Launch Momentum, Expanding CTCL Reach14 minutes ago | americanbankingnews.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Average Rating of "Hold" from BrokeragesSeptember 13, 2026 | americanbankingnews.comWhy This Small AI Company Holds 150 PatentsJeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11. | Brownstone Research (Ad)Citius Pharmaceuticals to Participate in September 2026 Investor ConferencesSeptember 3, 2026 | prnewswire.comCitius Pharmaceuticals Receives Nasdaq Extension to Regain ComplianceAugust 22, 2026 | theglobeandmail.comCitius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | prnewswire.comSee More Citius Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your email. Email Address About Citius PharmaceuticalsCitius Pharmaceuticals (NASDAQ:CTXR) (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for underserved areas of healthcare. The company has historically concentrated on anti-infective therapies, oncology treatments and supportive-care products, with an emphasis on therapies that address significant unmet medical needs. Citius’ lead programs have included Mino-Lok, an investigational antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while preserving the catheter. The company has also developed LYMPHIR (denileukin diftitox-cxdl), an oncology therapy for adults with relapsed or refractory cutaneous T-cell lymphoma. LYMPHIR received approval from the U.S. Food and Drug Administration in 2024 and is being advanced through the company’s oncology operations. The company’s activities have primarily focused on the U.S. market and on obtaining regulatory approval and commercializing specialty therapies. Citius Pharmaceuticals was founded in 2010 and is headquartered in New Jersey. Its leadership has included Myron Holubiak as chief executive officer and Leonard Mazur as chairman, although management roles may change over time.View Citius Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
